A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects With Presbyopia

Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia

Start Date04 Mar 2024

Sponsor / Collaborator

LENZ Therapeutics, Inc.

NCT06045299

/ CompletedPhase 3

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia

Start Date27 Sep 2023

Sponsor / Collaborator

LENZ Therapeutics, Inc.

NCT05936489

/ CompletedPhase 1

A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.

Start Date06 Jul 2023

Sponsor / Collaborator

LENZ Therapeutics, Inc.

[+1]

100 Clinical Results associated with Aceclidine

100 Translational Medicine associated with Aceclidine

100 Patents (Medical) associated with Aceclidine

161

Literatures (Medical) associated with Aceclidine

01 Apr 2025·MOLECULAR DIVERSITY

From antibiotic to antiviral: computational screening reveals a multi-targeting antibiotic from Streptomyces spp. against Nipah virus fusion proteins

Article

Author: Orosco, Fredmoore L ; Macalalad, Mark Andrian B ; Odchimar, Nyzar Mabeth O

Nipah Virus is a re-emerging zoonotic paramyxovirus that poses a significant threat to both swine industry and human health. The pursuit of potential antiviral agents with both preventive and therapeutic properties holds promise for targeting such viruses. To expedite this search, leveraging computational biology is essential. Streptomyces is renowned for its capacity to produce large and diverse metabolites with promising bioactivities. In the current study, we conducted a comprehensive structure-based virtual screening of 6524 Streptomyces spp. metabolites sourced from the StreptomeDB database to evaluate their potential inhibitory effects on three Nipah virus fusion (NiVF) protein conformations: NiVF pre-fusion 1-mer (NiVF-1mer), pre-fusion 3-mer (NiVF-3mer), and NiVF post-fusion (NiVF-PoF). Prior to virtual screening, the drug-likeness of Streptomyces spp. compounds was profiled using ADMET properties. From the 913 ADMET-filtered compounds, the subsequent targeted and confirmatory blind docking analysis revealed that S896 or virginiamycin M1, a known macrolide antibiotic, showed a maximum binding affinity with the NiVF proteins, suggesting a multi-targeting inhibitory property. In addition, the 200-ns molecular dynamics simulation and MM/PBSA analyses revealed stable and strong binding affinity between the NiVF-S896 complexes, indicating favorable interactions between S896 and the target proteins. These findings suggest the potential of virginiamycin M1, an antibiotic, as a promising multi-targeting antiviral drug. However, in vitro and in vivo experimental validations are necessary to assess their safety and efficacy.

01 Feb 2025·Computational and Theoretical Chemistry

Investigation of surface modified armchair type (5,5) single walled carbon nanotube with Si and B dopant atoms towards the evaluation of selective delivery of aceclidine drug: A DFT approach

Author: Akan, Emrah ; Baglayan, Ozge

Controlled drug delivery studies based on single walled carbon nanotubes (SWCNTs) have become an important research field.In the scope of this work, computational considerations based on the d. functional theory, the controlled and selective delivery attempts of silicon and boron decorated SWCNTs towards the aceclidine drug mol. were investigated.The structure and reactivity relationship together with some important diagnostic vibrational bands of double Si-B doped SWCNT and its interacted form with the aceclidine were investigated.It was observed that by selective determination of the interaction sites of aceclidine mol., it is possible to produce stable systems with Si and B-modified SWCNTs with acceptable recovery times for possible extended and selective drug delivery assessments.

01 Dec 2024·Annals of Phytomedicine-An International Journal

Biochemical and phytochemical analysis of Gypsophila (Gypsophila paniculata L.) using gas chromatography and mass spectroscopy (GC-MS)

Author: Anitha, T. ; Beaulah, A. ; Venkatesan, K. ; Keerthana, M. ; Rajadurai, K. R.

Gypsophila (Gypsophila paniculata L.) necessitates the evaluation of its constituents in various fields.To detail its quality, this research was conducted to assess the biochem. and phytochem. constituents of Gypsophila at the Department of Postharvest Technol., Horticultural College and Research Institute, Periyakulam from 2022 to 2024.The study was planned in a completely randomized design with three replications.It included boric acid, sucrose, and calcium chloride at different concentrations of 0.1 to 4%, alongside a control with distilled water.The results indicate that the combination of 2% boric acid, 2% sucrose and 0.2% calcium chloride (T2) was recorded in high levels of sugar content (9.3%), reducing sugar content (7.6%), protein content (18.1%), phenols content (3.9 mg/g), and carbohydrate content (7.2 mg/g).Major bioactive compounds identified in the Gypsophila including myo-inositol,4-C-methyl- (49.44%), stigmasterol (2.41%), hentriacontane (2.38%), 9-hexadecenoic acid (2.12%), benzoic acid, 4- ethoxy-, Et ester (1.70%), Bu di-Me (12 methyleicosyloxy), silane(1.58%), 3-methyl-4-phenyl1H-pyrrole (0.89%),vitamin E(1.33%), 2,4,7-tetra methyl-3,6,9-trioxa-2-siladecane (0.67%), ttetracosanoic acid (0.95 %), phytol(0.95%), ethanone,1-(2-hydroxy-5-Me phenyl)-(0.87%),1- azabicyclo hexane (0.80%), a-linolenic acid (0.59%), phenol,3,5bis (1,1dimethylethyl)-(0.69%), 21,3- propanedithiol (0.52%), 3-hydroxy-2,3-dihydromaltol (0.72%), and (3E,12Z)-nonadeca-1,3,12-triene5,14-diol (1.51%).

News (Medical) associated with Aceclidine

05 Jan 2026

·www.globenewswire.com

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZSAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. Lunatus will retain exclusive commercialization rights for VIZZ for the treatment of presbyopia in the Middle East region, including United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq. “As the commercial launch of VIZZ in the United States continues to build momentum, we are pleased to expand our network of commercial partnerships in key strategic regions outside the United States. Lunatus represents our fourth commercialization partnership for VIZZ, as we remain deeply committed to expanding global access to this transformative presbyopia therapy,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “Lunatus has built an outstanding reputation in the Middle East for high-quality execution, regulatory excellence and successful commercialization of innovative eye-care products. Their capabilities, combined with the growing unmet need for presbyopia solutions in the Middle East region, make this partnership a powerful fit. We look forward to working together to rapidly bring VIZZ to patients across the region.” “Partnering with LENZ Therapeutics marks an exciting step in expanding access to advanced eye-care solutions in the Middle East region,” said Dr. Lina Kouatly, President & CEO of Lunatus. “VIZZ represents a transformational advancement for patients living with presbyopia, offering the potential for greater visual independence and improved quality of life. With Lunatus’s established leadership in the ophthalmology market, regional infrastructure, and proven track record of delivering sustained double-digit growth in this field, we are confident in ensuring VIZZ’s successful launch and long-term value creation. We look forward to working closely with LENZ to deliver this therapy to patients who can benefit from it.” In July 2025, LENZ announced FDA approval of VIZZ for the treatment of presbyopia. VIZZ has been commercially available in the United States since September 30, 2025. About Presbyopia Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. About VIZZ (aceclidine ophthalmic solution) 1.44% VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. For more information, please visit www.VIZZ.com. VIZZ Indication and Important Safety Information INDICATION VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. IMPORTANT SAFETY INFORMATION Do not use VIZZ if allergic to any of the ingredients.To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving. For additional information, please see the full Prescribing Information available at www.VIZZ.com/full-prescribing-information.pdf. About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZTM (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com. About LunatusLunatus is a Dubai-based healthcare and pharmaceutical commercialisation partner serving the Arabian Gulf and broader Middle East. Founded in 2003, to act as the link between international healthcare companies and the expanding markets of the Arabian Gulf and Middle East. Lunatus provides turnkey representation to international healthcare companies, from regulatory submissions and local registration to marketing, sales, logistics and distribution enabling efficient market entry and sustainable commercial growth. Lunatus has partnered with a number of international pharma and healthcare companies, with a proven track record of introducing, building and maintaining profitable brand presence and has received awards as one of the top SMEs in the region. For more information, visit https://lunatus.com/ Contacts: Dan ChevallardLENZ TherapeuticsIR@LENZ-Tx.comMina Ashraf Vice President – Business Development & StrategyLunatusmina.ashraf@lunatus.com

License out/inDrug Approval

05 Jan 2026

·ir.lenz-tx.com

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. Lunatus will retain exclusive commercialization rights for VIZZ for the treatment of presbyopia in the Middle East region, including United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq. “As the commercial launch of VIZZ in the United States continues to build momentum, we are pleased to expand our network of commercial partnerships in key strategic regions outside the United States. Lunatus represents our fourth commercialization partnership for VIZZ, as we remain deeply committed to expanding global access to this transformative presbyopia therapy,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “Lunatus has built an outstanding reputation in the Middle East for high-quality execution, regulatory excellence and successful commercialization of innovative eye-care products. Their capabilities, combined with the growing unmet need for presbyopia solutions in the Middle East region, make this partnership a powerful fit. We look forward to working together to rapidly bring VIZZ to patients across the region.” “Partnering with LENZ Therapeutics marks an exciting step in expanding access to advanced eye-care solutions in the Middle East region,” said Dr. Lina Kouatly, President & CEO of Lunatus. “VIZZ represents a transformational advancement for patients living with presbyopia, offering the potential for greater visual independence and improved quality of life. With Lunatus’s established leadership in the ophthalmology market, regional infrastructure, and proven track record of delivering sustained double-digit growth in this field, we are confident in ensuring VIZZ’s successful launch and long-term value creation. We look forward to working closely with LENZ to deliver this therapy to patients who can benefit from it.” In July 2025, LENZ announced FDA approval of VIZZ for the treatment of presbyopia. VIZZ has been commercially available in the United States since September 30, 2025. About Presbyopia Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. About VIZZ (aceclidine ophthalmic solution) 1.44% VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. For more information, please visit www.VIZZ.com. VIZZ Indication and Important Safety Information INDICATION VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. IMPORTANT SAFETY INFORMATION Do not use VIZZ if allergic to any of the ingredients. To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use. Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes. If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart. Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear. Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving. For additional information, please see the full Prescribing Information available at www.VIZZ.com/full-prescribing-information.pdf. About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZTM (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com. About Lunatus Lunatus is a Dubai-based healthcare and pharmaceutical commercialisation partner serving the Arabian Gulf and broader Middle East. Founded in 2003, to act as the link between international healthcare companies and the expanding markets of the Arabian Gulf and Middle East. Lunatus provides turnkey representation to international healthcare companies, from regulatory submissions and local registration to marketing, sales, logistics and distribution enabling efficient market entry and sustainable commercial growth. Lunatus has partnered with a number of international pharma and healthcare companies, with a proven track record of introducing, building and maintaining profitable brand presence and has received awards as one of the top SMEs in the region. For more information, visit https://lunatus.com/ Released January 5, 2026

License out/inDrug Approval

15 Dec 2025

·endpoints.news

Lenz discloses case of retinal tear in presbyopia eye drop patient

Lenz Therapeutics alarmed investors on Friday when it disclosed a report of a serious complication in a patient who took its commercial eye drop for blurry near vision. The drug, called Vizz, was approved in July to treat presbyopia. Since then, a case of retinal tear was reported to the FDA’s adverse event database known as FAERS. The system collects self-submitted reports from healthcare workers, patients and others, and “does not equate to a causal relationship,” Lenz wrote in a securities filing. The company’s stock $LENZ fell 26% following the announcement on Friday. Then on Monday afternoon, the stock was down 7%, pricing at about $17 per share. Rips in the retina, the light-sensitive tissue in the back of the eye, can cause vision problems such as floaters. TD Cowen analysts wrote in a note to investors on Friday that they expected “very understandable investor worry” in response to the FAERS report. But they noted that based on current information, the incident represents one case following at least 5,000 Vizz prescriptions, which doesn’t count many other patients who have likely received Vizz as well “given the substantial sampling.” Lenz told Endpoints News in an emailed statement on Monday that retinal tears occur naturally in roughly 25 per 100,000 people every year. “As real-world use of Vizz expands, occasional retinal events may be expected, and this initial case occurring in a patient with significant baseline risk, including past retinal tears, does not change our overall safety expectations for Vizz nor who should be prescribed it,” the company said. The patient is “recovering well,” according to Lenz’s securities filing. Vizz’s label carries a warning for rare cases of retinal tears, but Lenz told Endpoints that no patients experienced retinal tears in clinical trials for the drug. The TD Cowen analysts noted that a perceived risk of retinal detachment impacted the launch of AbbVie’s competitor product Vuity, beyond other efficacy problems for the drug. Vuity’s label notes that “rare cases of retinal detachment and retinal tear have been reported with miotics, including Vuity.” AbbVie won the first approval for a presbyopia eye drop in 2021, but reduced its marketing and sales efforts on the drug shortly thereafter. Lenz has claimed that Vizz is more effective than Vuity, and works longer. However, the company has not conducted a head-to-head trial comparing the products directly.

Drug Approval

100 Deals associated with Aceclidine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Aceclidine	S01EB08	DB13262

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Presbyopia	United States	LENZ Therapeutics, Inc.	31 Jul 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05728944 \| NCT05656027 (CLARITY-2, FDA_CDER) Manual	Phase 3	Presbyopia	-	VIZZ (CLARITY-1)	bymxrtohqt(gsiehcgadu) = idalzkrhxd srpvwksmrb (ibtrvkjmsk )	Positive	31 Jul 2025
				Brimonidine (CLARITY-1)	bymxrtohqt(gsiehcgadu) = qjcpodokpx srpvwksmrb (ibtrvkjmsk )
NCT06045299 (JX07001, NEWS) Manual	Phase 3	Presbyopia	300	LNZ100	ovkchotdvh(ncrftxeeaq) = whrqwkhtlt rnaisyfpxu (bswnoqxelg ) Met View more	Positive	28 Oct 2024
				Placebo	ovkchotdvh(ncrftxeeaq) = epqnnweofn rnaisyfpxu (bswnoqxelg ) Met View more
NCT05728944 \| NCT05753189 \| NCT05656027 (NEWS) Manual	Phase 3	Presbyopia	-	LNZ100	dwnmjpruzo(nhsifkjvjr) = ybuwtkxvzu gqsvnncxee (jhgedvixrn ) Met	Positive	13 Aug 2024
CLARITY (NEWS)	-	Presbyopia	1,059	醋克利定	hqubvedbdt(vszpxacllt) = iotiqjfioo cbeonaigme (gehuzzksoo )	Positive	03 Apr 2024
				vehicle	-

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis